Abstract
Objectives To investigate the impact of targeted vaccination strategies on morbidity and mortality due to COVID-19, as well as on the incidence of SARS-CoV-2, in India.
Design Mathematical modelling.
Settings Indian epidemic of COVID-19 and vulnerable population.
Data sources Country specific and age-segregated pattern of social contact, case fatality rate and demographic data obtained from peer-reviewed literature and public domain.
Model An age-structured dynamical model describing SARS-CoV-2 transmission in India incorporating uncertainty in natural history parameters was constructed.
Interventions Comparison of different vaccine strategies by targeting priority groups such as key workers including health care professionals, individuals with comorbidities (24 – 60 year), and all above 60.
Main outcome measures Incidence reduction and averted deaths in different scenarios, assuming that the current restrictions are fully lifted as vaccination is implemented.
Results The priority groups together account for about 18% of India’s population. An infection preventing vaccine with 60% efficacy covering all these groups would reduce peak symptomatic incidence by 20.6% (95% uncertainty intervals (CrI) 16.7 - 25.4), and cumulative mortality by 29.7% (95% CrI 25.8-33.8). A similar vaccine with ability to prevent symptoms (but not infection) will reduce peak incidence of symptomatic cases by 10.4% (95% CrI 8.4 – 13.0), and cumulative mortality by 32.9% (95% CrI 28.6 - 37.3). In the event of insufficient vaccine supply to cover all priority groups, model projections suggest that after keyworkers, vaccine strategy should prioritise all who are > 60, and subsequently individuals with comorbidities. In settings with weakest transmission, such as sparsely-populated rural areas, those with comorbidities should be prioritised after keyworkers.
Conclusions An appropriately targeted vaccination strategy would witness substantial mitigation of impact of COVID-19 in a country like India with wide heterogenity. ‘Smart vaccination’, based on public health considerations, rather than mass vaccination, appears prudent.
Strengths and limitation of this study
The model in this study is informed by age-dependent risk factors for SARS-CoV-2 infection among contacts, and is stratified by co-morbidities (diabetes and/or hypertension), and vaccination status.
Data on mortality and large-scale contact tracing from within India, and the recent national sero-survey results were used, which constituted a major strength of this investigation.
Distinguishing between ‘infection’ and ‘symptomatic disease ‘ preventing vaccines, the model was simulated under a range of scenarios for the basic reproduction number (R0).
Should they have been available, real life country-specific data on excess risks of deaths due to comorbidities would have added strength to the presented model.
Key priority group-specific data on social mixing and potential associated transmission was not available, and remained as a limitation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Authors (SM, BB and SP) acknowledge funding from the Indian Council of Medical Research, and NA acknowledges funding from the UK Medical Research council. No additional funding or grant support was utilised for execution of this study by the authors who remained supported by their respective institutes of affiliation as indicated while independently carrying out the present study. The respective institutions of the authors had no financial interest in the investigational work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not required.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The model code and dataset are publicly available at https://github.com/sandipccmb/COVID-19-vaccination-strategy.
